Scalper1 News
Cardiac device maker Abiomed (ABMD) beat fiscal Q2 estimates Thursday, but its implied second-half guidance disappointed the Street so much that shares tumbled nearly 30%. Abiomed’s earnings for the quarter that ended Sept. 30 jumped 89% over the year-earlier quarter to 17 cents a share, beating analysts’ consensus by 2 cents, according to Thomson Reuters. Sales climbed 47% to $76.4 million, about $2 million above the Street’s average estimate. Scalper1 News
Scalper1 News